To the full analysis
Allogene Therapeutics stock: balance sheet and debt
ALLOAllogene Therapeutics has a debt to equity ratio of 0.28.
Debt / Equity
0.28
Interest coverage
−50x
Current ratio
7.93
Cash & equivalents
$250.21M
Total assets
$415.91M
Equity ratio
70.3%
Goodwill
not reported separately
Net debt
−$166.96M
More cash than debt
Total assets and equity ratio
How large the balance sheet of Allogene Therapeutics, Inc. is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2017 | no data | not reported separately | not reported separately | no data | $0 |
| 2018 | $773.86M | $754K | not split out | 90.9% | −$686.89M |
| 2019 | $717.8M | $151K | not split out | 87.6% | −$477.51M |
| 2020 | $1.23B | not reported separately | not reported separately | 87.9% | −$774.13M |
| 2021 | $1.05B | not reported separately | not reported separately | 88.0% | −$384.17M |
| 2022 | $821.58M | not reported separately | not reported separately | 81.2% | −$416.2M |
| 2023 | $642.84M | not reported separately | not reported separately | 79.7% | −$353.58M |
| 2024 | $548.71M | not reported separately | not reported separately | 76.9% | −$201.72M |
| 2025 | $415.91M | not reported separately | not reported separately | 70.3% | −$166.96M |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.
Equity and debt
What the company owns and owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2017 | $0 | −$2K | $0 | 0 |
| 2018 | $721.35M | $703.16M | $34.46M | 0.05 |
| 2019 | $530.53M | $629.02M | $53.03M | 0.08 |
| 2020 | $827.91M | $1.08B | $53.78M | 0.05 |
| 2021 | $457.3M | $925.2M | $73.13M | 0.08 |
| 2022 | $517.32M | $666.88M | $101.12M | 0.15 |
| 2023 | $448.7M | $512.23M | $95.12M | 0.19 |
| 2024 | $292.48M | $422.18M | $90.76M | 0.21 |
| 2025 | $250.21M | $292.54M | $83.25M | 0.28 |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.